Advaxis Sinks On Delayed Disclosure Of Clinical Hold
This article was originally published in Scrip
Advaxis Inc. fell 25.8% in after-hours trading on Oct. 6 when the company said the US FDA placed a clinical hold on its investigational new drug (IND) application for axalimogene filolisbac (ADXS-HPV) – a disclosure that was made five days after Advaxis received word from the agency.
You may also be interested in...
Ports, Prosthetics Take Blame In Partial Hold For Aduro’s Immunotherapy Trials
Aduro hopes for a relatively quick resolution to a clinical hold for its LADD cancer vaccine studies instituted by the FDA based on listeria detected around indwelling ports in two patients.
Advaxis Advances Personalized Cancer Vaccines With Eye On Manufacturing Time, Cost
Advaxis is developing – now with help from partner Amgen – a personalized immunotherapy strategy with each patient's cancer vaccine based on their own tumor's specific neoepitopes.
Deal Watch: Roche Aborts But Regeneron, Amgen and Pfizer Sign Up
Deal activity over the past seven days sees Roche knock back Inovio a second time, Regeneron plan for its future via an alliance with Adicet Bio, Amgen supplement its preclinical pipeline with a candidate from Advaxis, and Pfizer shore up its gene therapy ambitions with an acquisition.